-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on VYNE Therapeutics, Lowers Price Target to $4.5

Benzinga·04/25/2025 14:14:26
Listen to the news
HC Wainwright & Co. analyst Joseph Pantginis maintains VYNE Therapeutics (NASDAQ:VYNE) with a Buy and lowers the price target from $5.75 to $4.5.